BARCELONA, Spain, May 18 /PRNewswire/ --
CeloNova BioSciences, Inc., today announced that it will showcase the technology behind the CATANIA(TM) Coronary Stent System featuring a NanoThin Polyzene(R)-F surface treatment as part of the Company's participation in the EuroPCR conference May 19-22.
The CATANIA(TM) Stent surface is modified with a highly lubricious smart polymer, Polyzene(R)-F, which is anti-thrombotic, anti-inflammatory, bacterial-resistant, and promotes healthy endothelial cell growth without stimulating platelet activation. The CATANIA(TM) stent effectively creates a new stent alternative, one that offers many of the clinical benefits of drug-eluting stents (DES), while addressing some of the significant ongoing concerns with current DES technology such as product cost, potential for thrombosis, and challenges associated with costly long-term dual anti-platelet therapy following treatment, including patient compliance and drug tolerance. During EuroPCR, CeloNova will participate in several activities to introduce attendees to the company and its technology.
CeloNova is excited to introduce our stent to attendees at EuroPCR. Our Polyzene(R)-F technology allows us to develop differentiated products and deliver excellent results, said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. Beginning with a symposium at noon on May 20, we will present clinical data from four studies demonstrating the excellent outcomes with the stent in both coronary and below the knee applications. The first-in-man patients had zero thrombosis, MI, or death through 18 months without taking long-term dual anti-platelet therapy. This is an unqualified success and an unprecedented finding.
The symposium, moderated by Gus Pichard of Washington Hospital Center and Christoph Nienaber of the University of Rostock, will feature presentations by Corrado Tamburino and Davide Capodanno of Ferrarotto University, Francesco Prati of Rome Heart Research, and Daniele Gasparini of the University of Udine. Professors Tamburino and Prati, along with Roxana Mehran and George Dangas of Columbia University Medical Center, and Thierry Corcos of Clinique Turin in Paris co-authored the first-in-man paper which was released in the Journal of the American College of Cardiology Interventions in March.
The rapid-exchange, cobalt-chromium CATANIA(TM) Stent is available in 60 sizes: in lengths from 8-38 mm and in eight diameters, from 2.0-4.0 mm. The proprietary nanothin Polyzene(R)-F polymer can be applied to or mixed with other substances to allow for a diverse range of bioscience and industrial applications on a multitude of substrates, including other polymers, metals and ceramics. Polyzene(R)-F can be customized for the desired application and applied in a variety of ways including as a coating, extrusion, weaving, or electro-spinning ranging in thickness from less than 50 nanometers to more than 200 nanometers. The base substrate will be endowed with the properties of the polymer. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe and the Middle East.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F, a highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. For more information, please visit www.celonova.com.
CONTACT: Teresa Wilson +1-770-502-0304
Teresa Wilson, CeloNova BioSciences, Inc., +1-770-502-0304 / Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18788, Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b